{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["8(1)"],"submitter":["Afkhami S"],"funding":["Gouvernement du Canada | Canadian Institutes of Health Research"],"pubmed_abstract":["Viral-vectored vaccines are highly amenable for respiratory mucosal delivery as a means of inducing much-needed mucosal immunity at the point of pathogen entry. Unfortunately, current monovalent viral-vectored tuberculosis (TB) vaccine candidates have failed to demonstrate satisfactory clinical protective efficacy. As such, there is a need to develop next-generation viral-vectored TB vaccine strategies which incorporate both vaccine antigen design and delivery route. In this study, we have developed a trivalent chimpanzee adenoviral-vectored vaccine to provide protective immunity against pulmonary TB through targeting antigens linked to the three different growth phases (acute/chronic/dormancy) of Mycobacterium tuberculosis (M.tb) by expressing an acute replication-associated antigen, Ag85"],"journal":["NPJ vaccines"],"pagination":["25"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9948798"],"repository":["biostudies-literature"],"pubmed_title":["Intranasal multivalent adenoviral-vectored vaccine protects against replicating and dormant M.tb in conventional and humanized mice."],"pmcid":["PMC9948798"],"pubmed_authors":["Ottenhoff THM","Xing Z","Yang JX","Chacon A","Vaseghi-Shanjani M","Zganiacz A","Franken KLMC","D'Agostino MR","Lepard M","Jeyanathan M","Gillgrass A","Choi MWY","Afkhami S","Lai R","Ertl HC"],"additional_accession":[]},"is_claimable":false,"name":"Intranasal multivalent adenoviral-vectored vaccine protects against replicating and dormant M.tb in conventional and humanized mice.","description":"Viral-vectored vaccines are highly amenable for respiratory mucosal delivery as a means of inducing much-needed mucosal immunity at the point of pathogen entry. Unfortunately, current monovalent viral-vectored tuberculosis (TB) vaccine candidates have failed to demonstrate satisfactory clinical protective efficacy. As such, there is a need to develop next-generation viral-vectored TB vaccine strategies which incorporate both vaccine antigen design and delivery route. In this study, we have developed a trivalent chimpanzee adenoviral-vectored vaccine to provide protective immunity against pulmonary TB through targeting antigens linked to the three different growth phases (acute/chronic/dormancy) of Mycobacterium tuberculosis (M.tb) by expressing an acute replication-associated antigen, Ag85","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Feb","modification":"2025-04-19T00:55:30.542Z","creation":"2025-04-07T11:53:04.745Z"},"accession":"S-EPMC9948798","cross_references":{"pubmed":["36823425"],"doi":["10.1038/s41541-023-00623-z"]}}